• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations

tetano

Editor, Senior Moderator
Cell Rep


. 2022 Oct 18;41(3):111496.
doi: 10.1016/j.celrep.2022.111496.
SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations


Elizabeth M Anderson[SUP] 1 [/SUP], Shuk Hang Li[SUP] 1 [/SUP], Moses Awofolaju[SUP] 1 [/SUP], Theresa Eilola[SUP] 1 [/SUP], Eileen Goodwin[SUP] 1 [/SUP], Marcus J Bolton[SUP] 1 [/SUP], Sigrid Gouma[SUP] 1 [/SUP], Tomaz B Manzoni[SUP] 1 [/SUP], Philip Hicks[SUP] 1 [/SUP], Rishi R Goel[SUP] 2 [/SUP], Mark M Painter[SUP] 2 [/SUP], Sokratis A Apostolidis[SUP] 3 [/SUP], Divij Mathew[SUP] 2 [/SUP], Debora Dunbar[SUP] 4 [/SUP], Danielle Fiore[SUP] 5 [/SUP], Amanda Brock[SUP] 6 [/SUP], JoEllen Weaver[SUP] 6 [/SUP], John S Millar[SUP] 7 [/SUP], Stephanie DerOhannessian[SUP] 8 [/SUP], UPenn COVID Processing Unit; Allison R Greenplate[SUP] 9 [/SUP], Ian Frank[SUP] 4 [/SUP], Daniel J Rader[SUP] 8 [/SUP], E John Wherry[SUP] 10 [/SUP], Paul Bates[SUP] 1 [/SUP], Scott E Hensley[SUP] 11 [/SUP]



Affiliations

Abstract

It is important to determine if severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and SARS-CoV-2 mRNA vaccinations elicit different types of antibodies. Here, we characterize the magnitude and specificity of SARS-CoV-2 spike-reactive antibodies from 10 acutely infected health care workers with no prior SARS-CoV-2 exposure history and 23 participants who received SARS-CoV-2 mRNA vaccines. We found that infection and primary mRNA vaccination elicit S1- and S2-reactive antibodies, while secondary vaccination boosts mostly S1 antibodies. Using absorption assays, we found that SARS-CoV-2 infections elicit a large proportion of original antigenic sin-like antibodies that bind efficiently to the spike of common seasonal human coronaviruses but poorly to the spike of SARS-CoV-2. In converse, vaccination modestly boosts antibodies reactive to the spike of common seasonal human coronaviruses, and these antibodies cross-react more efficiently to the spike of SARS-CoV-2. Our data indicate that SARS-CoV-2 infections and mRNA vaccinations elicit fundamentally different antibody responses.

Keywords: CP: Immunology; SARS-CoV-2; antibodies; coronavirus; mRNA vaccines; original antigenic sin.
 
Back
Top Bottom